A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study is a trial of dexanabinol in patients with advanced tumours. The purposes of the
protocol are to study different doses of the study drug to determine the maximum safe dose of
the drug given in combination with standard chemotherapies and to further understand the
safety of the study drug and to measure any reduction in size of patients' cancer tumour(s).
Dexanabinol is a synthetic cannabinoid which has previously undergone clinical trials for
traumatic brain injury (TBI) and in subjects undergoing coronary artery bypass surgery.
Currently dexanabinol is under investigation for potential anti-tumour activity in patients
with advanced tumours.
Phase:
Phase 1
Details
Lead Sponsor:
e-Therapeutics PLC
Treatments:
Dronabinol Gemcitabine HU 211 Paclitaxel Sorafenib